Does IRadimed Corporation's (NASDAQ:IRMD) August Stock Price Reflect Its Future Growth?

IRadimed Corporation (NASDAQ:IRMD) is considered a high-growth stock, but its last closing price of $19.31 left some investors wondering if this high future earnings potential can be rationalized by its current price tag. Let’s look into this by assessing IRMD's expected growth over the next few years.

See our latest analysis for IRadimed

Can we expect IRMD to keep growing?

The excitement around IRadimed's growth potential is not unfounded. Analyst consensus expectation is extremely bullish with earnings forecasted to rise significantly from today's level of $0.732 to $1.217 over the next three years. This indicates an estimated earnings growth rate of 29% per year, on average, which indicates an exceedlingly positive future in the near term.

Is IRMD's share price justifiable by its earnings growth?

IRMD is trading at price-to-earnings (PE) ratio of 26.39x, which suggests that IRadimed is undervalued based on its latest annual earnings update compared to the Medical Equipment average of 40.65x , and overvalued compared to the US market average ratio of 16.99x .

Given that IRMD's price-to-earnings of 26.39x lies below the industry average, this already indicates that the company could be potentially undervalued. However, to be able to properly assess the value of a high-growth stock such as IRadimed, we must incorporate its earnings growth in our valuation. The PEG ratio is a great calculation to take account of growth in the stock's valuation. A PE ratio of 26.39x and expected year-on-year earnings growth of 29% give IRadimed a low PEG ratio of 0.90x. This tells us that when we include its growth in our analysis IRadimed's stock can be considered fairly valued , based on its fundamentals.

What this means for you:

IRMD's current undervaluation could signal a potential buying opportunity to increase your exposure to the stock, or it you're a potential investor, now may be the right time to buy. However, basing your investment decision off one metric alone is certainly not sufficient. There are many things I have not taken into account in this article and the PEG ratio is very one-dimensional. If you have not done so already, I urge you to complete your research by taking a look at the following:

1. Financial Health: Are IRMD’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.
2. Past Track Record: Has IRMD been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of IRMD's historicals for more clarity.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.